Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02104375
Recruitment Status : Completed
First Posted : April 4, 2014
Last Update Posted : March 10, 2015
Sponsor:
Information provided by (Responsible Party):
Arturo Figueroa, Florida State University

Brief Summary:

Cardiovascular disease (CVD) continues to be the major cause of morbidity and mortality in western countries. It has been shown that CVD events are known to be higher in the winter than in the summer. Low environmental temperatures may induce increased cardiovascular stress resulting in cold-induced hypertension (CIH), the leading risk factor for CVD events. Similar to whole-body cold exposure, the cold pressor test (CPT), an external local cold stimulus, has been used for evaluation of cardiovascular and hemodynamic reactivity to sympathetic stimulation. It has been shown that brachial blood pressure (BP), pressure pulse wave reflection, aortic BP, heart rate (HR), and arterial stiffness are increased during CPT. However, the physiologic mechanisms for the cardiovascular complications related to low temperatures are not completely clear.

Isometric-handgrip (IHG) exercise has been used as a tool for assessing cardiovascular autonomic control by a maneuver defined as post-exercise muscle ischemia (PEMI). PEMI induces exercise pressor reflex (metaboreflex) by trapping metabolites in the previous active muscle at the cessation of exercise. During PEMI, the accumulation of contraction-derived metabolites induces sympathetic mediated vascular stimulation and an increased BP, whereas the HR fully recovers. This suggests that the fall in HR is evoked by an increase in parasympathetic activity which overpowers the sympathetic activation. Implication of IHG exercise followed by PEMI provides important clinical information because impaired autonomic and cardiovascular functions are associated with cardiovascular events.

Recently, oral supplementation with the amino acid L-citrulline (L-cit) has been proposed as a possible adjunct treatment for hypertension and arterial stiffness. L-cit is known to enhance the bioavailability of L-arginine (L-arg), the endothelial substrate for nitric oxide (NO) production. Cold exposure might include a temperature-dependent inhibition of endothelial NO synthase (eNOS), the enzyme that produces NO from the amino acid L-arg and may trigger various types of CVD. It has been shown that L-cit supplementation has effectively attenuated the CIH response during cold pressor test. Thus, L-cit supplementation may be effective to reduce the cardiovascular responses associated with cold exposure and the exercise pressor reflex imposed by PEMI. Therefore, the proposed study is important for the following reasons: (1) the results of his study will add to our understanding regarding the cardiovascular and autonomic mechanisms associated with exercise and cold exposure; (2) the results of this study will contribute to the development of an adjunct therapy for the prevention of cardiovascular adverse events that are particularly increased during stress such as cold exposure and exercise.


Condition or disease Intervention/treatment Phase
Hypertension Dietary Supplement: L-citrulline Phase 1 Phase 2

Detailed Description:

Specific Aims

AIM 1: To determine the acute effects of the exercise pressor response imposed by PEMI with and without CPT on hemodynamics and cardiac autonomic regulation in health overweight/obese men.

AIM 2: To examine the effects of a 14-day course of L-cit supplementation on arterial stiffness, aortic hemodynamics, and autonomic regulation at rest and during conditions characterized by increased sympathetic activity (IHG, PEMI, and PEMI concurrent with CPT).

Research Hypotheses

Hypothesis 1: There will be greater increases in peripheral and central BP, arterial stiffness, wave reflection, and cardiac sympathetic activity during PEMI concurrent with CPT than during PEMI alone.

Hypothesis 2: 14 days of L-cit supplementation will attenuate peripheral and central BP, wave reflection, arterial stiffness, and cardiac sympathetic activity responses during IHG exercise, PEMI, and PEMI concurrent with CPT compared with placebo (PL) supplementation.

Description of the study

A total of twenty male young adults (18-35 years) with overweight or obesity [body mass index (BMI) >25 and <40 kg/m2] will be enrolled in this study. All of the subjects will be nonsmokers, no L-cit or L-arg users or regular exercisers (defined as more than 120 min per week) at least 6 months before the study begins. Subjects will be asked to maintain their diet and exercise habits during the study period.

Study design:

After completion of initial screening, cardiovascular and autonomic function of eligible subjects will be evaluated in a quiet temperature-controlled room (22-24°C). After baseline measurement, in a cross-over design fashion, subjects will be randomized to either Placebo group (Maltodextrin) or L-citrulline group for the first 14 days of the study that will be followed by a 14 day washout period and then will be crossed over to their next treatment. Cardiovascular function will be evaluated at baseline and after 14 days of the first and the second treatment. Measurements will be conducted in the morning after at least 8 hours of an overnight fast in order to avoid potential diurnal variations in BP and vascular reactivity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia
Study Start Date : March 2013
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: L-citrulline
L-citrulline (6 g/day for 2 weeks)
Dietary Supplement: L-citrulline
2 weeks of L-citrulline supplementation (6g/day).
Other Name: 2 weeks of L-citrulline supplementation (6g/day).

Placebo Comparator: Maltodextrin
6g/day of placebo (maltodextrin)
Dietary Supplement: L-citrulline
2 weeks of L-citrulline supplementation (6g/day).
Other Name: 2 weeks of L-citrulline supplementation (6g/day).




Primary Outcome Measures :
  1. Blood Pressure [ Time Frame: 6 weeks ]
    By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)


Secondary Outcome Measures :
  1. Arterial Stiffness [ Time Frame: 6 weeks ]
    By measuring brachial-ankle pulse wave velocity at rest and during physiological stress (cold pressor test, post-exercise muscle ischemia, and handgrip test)


Other Outcome Measures:
  1. Autonomic control of heart rate [ Time Frame: 6 weeks ]
    By measuring heart rate variability at rest and during physiological stress.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Men
  • Blood pressure lower than 140/90mmHg
  • Age 18 to 35 years
  • BMI 25-39 kg/m2

Exclusion Criteria:

  • Blood Pressure >160/100 mmHg
  • Asthma
  • Glaucoma
  • Herpes simplex
  • Uncontrolled diabetes
  • Neurological disease
  • Cardiovascular disease
  • Inflammatory disease
  • Kidney disease
  • Hormone replacement therapy (HRT)
  • Amino acid/vitamin supplementation\
  • Corticosteroids or non-steroidal anti-inflammatory drugs
  • Any drug known to affect BP or heart rate
  • Glycemic control drugs
  • Lipids reducing drugs
  • Participants should not consume > 12 alcoholic drink/week
  • Smokers
  • Regular Exercisers (>1.5 hour/week).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02104375


Locations
Layout table for location information
United States, Florida
FSU College of Human Sciences
Tallahassee, Florida, United States, 32306
Sponsors and Collaborators
Florida State University
Investigators
Layout table for investigator information
Principal Investigator: Arturo Figueroa Florida State University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Arturo Figueroa, Associate Professor, Florida State University
ClinicalTrials.gov Identifier: NCT02104375    
Other Study ID Numbers: 2013.11742
First Posted: April 4, 2014    Key Record Dates
Last Update Posted: March 10, 2015
Last Verified: March 2015
Keywords provided by Arturo Figueroa, Florida State University:
wave reflection
augmentation Index
heart rate variability
arterial stiffness
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Pathologic Processes